Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, June 24 at 2:00 PM EDT

Register Free →

This Government Contract opportunity from Department Of Defense was posted on May 15, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Realistic Mass Casualty Medical Simulation Capabilities RFI

Closed
DARPA-SN-26-79Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541714
New
Federal
TECHNOLOGY LICENSING OPPORTUNITY: DC RecruiterDC Recruiter is an innovative immune-enhancing technology developed by scientists at Los Alamos National Laboratory that uses a self-assembling peptide nanofiber to recruit and activate dendritic cells, critical components of the immune system. Unlike traditional pathogen-specific vaccines and treatments, this approach is designed to trigger an early, broad-spectrum immune response regardless of the specific infectious agent. The product is formulated as a needle-free, spray-friendly application, enhancing its practicality and ease of use in various settings. Its core advantage lies in addressing the challenge of rapid immune activation before the pathogen is identified, providing fast-acting defense during exposure scenarios where conventional methods may be delayed, too specific, or ineffective. This technology holds promise across multiple market sectors, including infectious disease prevention, outbreak management, national defense, consumer health, pharmaceuticals, and emergency preparedness. Its broad, pathogen-agnostic mechanism makes it especially valuable in high-risk or field environments requiring quick deployment and flexible administration. Currently at a technology readiness level of 3, DC Recruitor is patent-pending and available for licensing through Los Alamos National Laboratory’s program, which facilitates exclusive and non-exclusive licensing agreements to commercial partners seeking to leverage cutting-edge innovations for competitive advantage. The ongoing solicitation invites potential collaborators to engage before the stated deadline.
Triad - DOE Contractor

POSTED

2 days ago

DEADLINE

in 6 months
NAICS: 541714
New
Federal
Contact Activation Pathway Function Blocking Antibody AB023The Defense Health Agency is conducting a Request for Information (RFI) to gather market intelligence and identify qualified sources for the supply of the contact activation pathway function blocking antibody AB023, also known as Xisomab 3G3 or Gruticibart. This antibody is designed to inhibit Coagulation Factor XI (FXI) by targeting the "apple 2" domain, preventing its activation by activated factor XII (FXIIa) in the contact pathway, which is implicated in clot formation on artificial surfaces. The antibody is intended for use in medical applications such as Extracorporeal Membrane Oxygenation (ECMO) circuits, hemodialysis, catheters, and cancer-associated thrombosis. It is designed to preserve natural clotting processes by not interfering with FXI activation by thrombin or the conversion of Factor IX by activated FXI, thus maintaining normal hemostasis required for wound healing. The Government anticipates procuring up to 0.5 grams of AB023 annually and requires pharmacokinetic and pharmacodynamic testing to assess its concentration over time, biochemical impacts, clotting time effects, and ability to prevent thrombus growth and fibrin accumulation in vascular thrombosis models. Stability, dosage, and potency validations must be conducted using clotting assays. Although this announcement does not represent a solicitation or obligation to award a contract, interested parties with relevant expertise must submit technical information by June 18, 2026. All responders must be registered in the System for Award Management (SAM). The associated NAICS code is 541714, reflecting research and development in biotechnology. The point of contact is based at the Defense Health Agency in Fort Detrick, Maryland, with the place of performance listed in Texas.
Defense Health Agency

POSTED

5 days ago

DEADLINE

in 1 day

AI Contract Overview

Show more

The Defense Advanced Research Projects Agency's Biological Technologies Office is seeking insights from a broad spectrum of organizations, including industry, government support entities, military training groups, and civilian emergency preparedness agencies, on their capabilities to plan, resource, execute, and evaluate high-fidelity mass casualty medical simulations. These simulations are intended to realistically portray large-scale casualty events involving more than 50, 100, or 200 simulated patients within a single exercise lasting under 72 hours. The objective is to understand current capabilities for conducting such complex and large medical simulation events. This Request for Information, identified as DARPA-SN-26-79 and posted on May 15, 2026, serves exclusively for information gathering and planning purposes and does not represent a solicitation for proposals or funding opportunities. Responses are due by May 31, 2026, at 4:00 PM. The initiative is aimed at enhancing preparedness for mass casualty incidents through realistic training exercises and assessments but does not commit the agency to any procurement. Correspondence regarding the RFI can be directed to Dr. Jeremy Pamplin at the Biological Technologies Office in Arlington, VA.

General Info

DARPA seeks information on capabilities for large-scale, high-fidelity mass casualty medical simulations.

Agency

Department Of Defense → Defense Advanced Research Projects Agcy

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

VA

Set-Aside

NONE

Documents

(1)

DARPA-SN-26-79 Realistic Mass Casualty Medical Simulation Capabilities RFI

PDFrfi

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

Timeline

PhaseClosed
Posted

special-notice

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → Defense Advanced Research Projects Agcy
Contacts1 person available
OfficeARLINGTON, VA, 222032114, USA
Organization / Agency
Department Of Defense → Defense Advanced Research Projects Agcy
Office AddressARLINGTON, VA, 222032114, USA
Contacts
Dr. Jeremy Pamplin DARPA/BTO

Full Description

Show more
The Biological Technologies Office (BTO) of the Defense Advanced Research Projects Agency
(DARPA) seeks input from industry, government support organizations, military training organizations, and civilian emergency preparedness entities regarding capabilities to plan, resource, execute, and assess high-fidelity, large-scale mass casualty (MASCAL) medical simulation events. This Request for Information (RFI) is a preliminary step to assess current capabilities to conduct realistic MASCAL simulations involving greater than 50, 100, or 200 simulated patients within a single event lasting less than 72 hours.

This RFI is solely for information gathering and planning purposes. It does not constitute a solicitation for proposals, abstracts, or quotations nor indicate an intent to fund those who respond.